RotaTeq is a live, oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis.
Pablo Legorreta, CEO of Royalty Pharma, said: “With the addition of this royalty on RotaTeq, we further our strategy of building a highly diversified portfolio of royalty interests on leading biopharmaceutical products. We are pleased to add the first vaccine to complement our royalties on products that treat a wide range of diseases, including cancer, rheumatoid arthritis and other autoimmune disorders, AIDS/HIV and neuropathic pain.”